- Drug Pipelines
- August 2024
- 180 Pages
Global
From €2397EUR$2,500USD£2,003GBP
- Report
- June 2024
- 200 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Report
- May 2024
- 71 Pages
Global
From €3830EUR$3,995USD£3,200GBP
- Report
- May 2024
- 138 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- November 2023
- 276 Pages
Global
From €9107EUR$9,500USD£7,610GBP
- Report
- January 2022
- 200 Pages
Global
From €7190EUR$7,500USD£6,008GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
The HER2 Positive Breast Cancer Drug market is a subset of the larger Breast Cancer Drug market. HER2 Positive Breast Cancer Drugs are used to treat breast cancer that is positive for the HER2 gene. These drugs work by targeting the HER2 gene, which is overexpressed in some breast cancer cells. HER2 Positive Breast Cancer Drugs are typically used in combination with other treatments, such as chemotherapy and radiation.
The HER2 Positive Breast Cancer Drug market is highly competitive, with many companies offering different treatments. Some of the major players in the market include Roche, Novartis, Pfizer, AstraZeneca, and Eli Lilly. These companies offer a variety of treatments, including monoclonal antibodies, small molecule inhibitors, and targeted therapies. Show Less Read more
